Renaissance Technologies
PRME icon

Renaissance Technologies’s Prime Medicine PRME Stock Holding History

Renaissance Technologies’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Sell
117,412
-623,627
-84% -$2.07M ﹤0.01% 2652
2026
Q1 		$2.58M Sell
741,039
-408,120
-36% -$1.55M ﹤0.01% 1742
2025
Q4 		$3.99M Buy
1,149,159
+14,489
+1% +$64.4K 0.01% 1439
2025
Q3 		$6.29M Buy
1,134,670
+911,270
+408% +$3.7M 0.01% 1358
2025
Q2 		$552K Sell
223,400
-224,200
-50% -$346K ﹤0.01% 2785
2025
Q1 		$891K Buy
+447,600
New +$1.14M ﹤0.01% 2486
2024
Q4 		– Sell
-20,000
Closed -$77.4K – 3836
2024
Q3 		$77.4K Buy
+20,000
New +$92.6K ﹤0.01% 3296
2024
Q2 		– Sell
-362,400
Closed -$2.54M – 3870
2024
Q1 		$2.54M Buy
362,400
+309,108
+580% +$2.34M ﹤0.01% 1870
2023
Q4 		$472K Buy
+53,292
New +$411K ﹤0.01% 2808

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Renaissance Technologies's PRME Position: Q2 2026 in Review

Renaissance Technologies reduced its Prime Medicine (PRME) stake by 84% in Q2 2026, selling an estimated $2.07M and leaving 117,412 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #2652.

Renaissance Technologies first reported a position in PRME in Q4 2023 and has held it in 9 quarters since. The position peaked at $6.29M in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Renaissance Technologies held 117,412 shares of Prime Medicine worth $433K as of Q2 2026.
  • Renaissance Technologies sold 623,627 Prime Medicine shares in Q2 2026, an estimated $2.07M.
  • Prime Medicine made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2652 holding.
  • Renaissance Technologies first reported a position in Prime Medicine in Q4 2023 and has held it in 9 quarters since.
  • Renaissance Technologies's Prime Medicine position peaked at $6.29M in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.